IPO Listing: This IPO will be listed in the stock market tomorrow, profit of Rs 9 per share is expected

News Topical, Digital Desk : IPO Listing: After receiving a tremendous response from the market, Amanta Healthcare is now set to make its debut in the stock market on Tuesday (September 9, 2025). Ahead of listing, the company's shares are trading at a premium of Rs 9 in the gray market. This is about 7.14% higher than the upper price band of Rs 126 per share. Most investors keep an eye on GMP to estimate the listing value.

Enthusiasm seen among investors 

Amanta Healthcare's IPO was open for subscription between 1 and 3 September. There has been a lot of interest in the market for this. The issue has received a total subscription of 82.61 times. During this period, non-institutional investors (NIIs) subscribed 209.42 times, retail investors 54.98 times and qualified institutional investors (QIBs) subscribed the issue 35.86 times. The price band of the IPO was Rs 120-126 per share. Through this, 1 crore new shares have been issued, whose value is Rs 126 crore. Before the IPO, the company had raised Rs 37.8 crore from 6 institutional investors through anchor book on 29 August. Meanwhile, at a post-issue valuation of around Rs 500 crore, Amanta Healthcare plans to spend Rs 70 crore to expand its sterile manufacturing line and Rs 30.1 crore to set up a new small volume parenterals (ABFS) line. Apart from this, the remaining funds will be used for general corporate purposes. A look at the company  Amanta Healthcare started in December 1994. It is engaged in the development, manufacturing and marketing of sterile liquid pharmaceuticals, especially parenteral products. Their packaging is done using advanced aseptic blow-fill-seal (ABFS) and injection stretch blow molding (ISBM) technologies. The company also manufactures medical devices. Amanta Healthcare has a strong position in the domestic market with more than 320 distributors and stockists. Along with this, it also exports to Africa, Latin America, UK and other emerging markets. In FY25, 55% of revenue came from domestic branded generic drugs, 33% from international sales and 10% from product partnerships and contract manufacturing. Looking at the business figures , the company reported a revenue of Rs 274.7 crore in FY25, slightly lower than Rs 280.3 crore in FY24. However, profitability has improved in the meantime. Its profit increased from Rs 3.6 crore in FY24 to Rs 10.5 crore in FY25.
 

Read More: Vodafone Idea gave big information on the exchange - said that for the first time in 4 years the rating has been so good, also told about the future planning